These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10114373)

  • 21. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
    Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicare program; changes to Medicare payment for drugs and physician fee schedule payments for calendar year 2004. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Jan; 69(4):1083-267. PubMed ID: 14968797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2000. Health Care Financing Administration (HCFA), HHS. Final rule with comment period.
    Fed Regist; 1999 Nov; 64(211):59380-590. PubMed ID: 11010693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical devices; Mammography Quality Standards Act of 1992; inspection fees--FDA. Notice.
    Fed Regist; 1995 Mar; 60(52):14584-6. PubMed ID: 10141780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical devices; 30-day notices and 135-day PMA (premarket approval application) supplement review--FDA. Direct final rule.
    Fed Regist; 1998 Apr; 63(80 Pt 1):20530-3. PubMed ID: 10179319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA's mammography facility quality assurance program.
    Kivel M
    Adm Radiol; 1994 Feb; 13(2):43-4. PubMed ID: 10132931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(94):26657-70. PubMed ID: 10558516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Requirements for accrediting bodies of mammography facilities--FDA. Interim rule with request for comments.
    Fed Regist; 1993 Dec; 58(243):67558-65. PubMed ID: 10131224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human tissue intended for transplantation--FDA. Interim rule; opportunity for public comment.
    Fed Regist; 1993 Dec; 58(238):65514-21. PubMed ID: 10131341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical devices; establishment registration and device listing for manufacturers and distributors of devices--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(188):51825-7. PubMed ID: 10185812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical devices; reports of corrections and removals--FDA. Direct final rule.
    Fed Regist; 1998 Aug; 63(152):42229-33. PubMed ID: 10181725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. General and plastic surgery devices; effective date of requirement for premarket approval of the silicone inflatable breast prosthesis. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
    Fed Regist; 1999 Aug; 64(160):45155-61. PubMed ID: 10558602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human cells, tissues, and cellular and tissue-based products; establishment registration and listing. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jan; 69(17):3823-6. PubMed ID: 14968801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare program; determination of reasonable charges. Health Care Financing Administration. Interim final rule with a comment period.
    Fed Regist; 1981 Dec; 46(251):63273-4. PubMed ID: 10298358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2004. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Nov; 68(216):63195-395. PubMed ID: 14610760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.